Artículos por temáticas

Genetic counseling and testing practices for late-onset neurodegenerative disease: a systematic review

Crook A, Jacobs C, Newton-John T, O'Shea R, McEwen A.

J Neurol. 2022 Feb;269(2):676-692. doi: 10.1007/s00415-021-10461-5. Epub 2021 Mar 1.

XK-Associated McLeod Syndrome: Nonhematological Manifestations and Relation to VPS13A Disease

Peikert K, Hermann A, Danek A.

Transfus Med Hemother. 2022 Jan 25;49(1):4-12. doi: 10.1159/000521417. eCollection 2022 Feb.

Deciphering the role of PGC-1α in neurological disorders: from mitochondrial dysfunction to synaptic failure

Panes JD, Wendt A, Ramirez-Molina O, Castro PA, Fuentealba J.

Neural Regen Res. 2022 Feb;17(2):237-245. doi: 10.4103/1673-5374.317957.

Salivary biomarkers of neurodegenerative and demyelinating diseases and biosensors for their detection

Goldoni R, Dolci C, Boccalari E, Inchingolo F, Paghi A, Strambini L, Galimberti D, Tartaglia GM.

Ageing Res Rev. 2022 Apr;76:101587. doi: 10.1016/j.arr.2022.101587. Epub 2022 Feb 11.

Orofacial manifestations of chorea-acanthocytosis: case presentation and literature review

Zamora JG, Rivera C, Utsman R, Klasser GD.

Quintessence Int. 2022 Feb 1;53(3):270-276. doi: 10.3290/j.qi.b2407809.

One Side of the Story; Clues to Etiology in Patients with Asymmetric Chorea

Cincotta M, Walker RH.

Tremor Other Hyperkinet Mov (N Y). 2022 Jan 31;12:3. doi: 10.5334/tohm.675. eCollection 2022.

Advances in Modeling Polyglutamine Diseases Using Genome Editing Tools

Karwacka M, Olejniczak M.

Cells. 2022 Feb 2;11(3):517. doi: 10.3390/cells11030517.

Partners in crime: Proteins implicated in RNA repeat expansion diseases

Baud A, Derbis M, Tutak K, Sobczak K.

Wiley Interdiscip Rev RNA. 2022 Feb 28:e1709. doi: 10.1002/wrna.1709. Online ahead of print.

Measuring movement in health and disease

Rebec GV, Koceja DM, Bunner KD.

Brain Res Bull. 2022 Apr;181:167-174. doi: 10.1016/j.brainresbull.2022.01.021. Epub 2022 Feb 2.

Autophagy system as a potential therapeutic target for neurodegenerative diseases

Cui M, Yoshimori T, Nakamura S.

Neurochem Int. 2022 May;155:105308. doi: 10.1016/j.neuint.2022.105308. Epub 2022 Feb 15.

Mitochondrial ATP Synthase is a Target of Oxidative Stress in Neurodegenerative Diseases

Ebanks B, Chakrabarti L.

Front Mol Biosci. 2022 Feb 14;9:854321. doi: 10.3389/fmolb.2022.854321. eCollection 2022.

Involvement of molecular chaperone in protein-misfolding brain diseases

Wankhede NL, Kale MB, Upaganlawar AB, Taksande BG, Umekar MJ, Behl T, Abdellatif AAH, Bhaskaran PM, Dachani SR, Sehgal A, Singh S, Sharma N, Makeen HA, Albratty M, Dailah HG, Bhatia S, Al-Harrasi A, B

Biomed Pharmacother. 2022 Mar;147:112647. doi: 10.1016/j.biopha.2022.112647. Epub 2022 Feb 8.

Novel Neuronal Autoantibodies in Huntington's Disease

Endres D, Werden R, Schweizer T, Schröter N, Schiele MA, Nickel K, Fischer M, Domschke K, Urbach H, Meyer PT, Prüss H, Tebartz van Elst L.

Biol Psychiatry. 2022 Feb 15;91(4):e21-e23. doi: 10.1016/j.biopsych.2020.12.032. Epub 2021 Mar 12.

Clozapine treatment for Huntington's disease psychosis

Bampton TJ, Hack D, Galletly CA.

Aust N Z J Psychiatry. 2022 Feb;56(2):200. doi: 10.1177/00048674211013082. Epub 2021 May 13.

Polyglutamine diseases

Bunting EL, Hamilton J, Tabrizi SJ.

Curr Opin Neurobiol. 2022 Feb;72:39-47. doi: 10.1016/j.conb.2021.07.001. Epub 2021 Sep 3.